Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Elevation Oncology Inc (ELEV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/26/2025: ELEV (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 78.45% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 03/26/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 15.39M USD | Price to earnings Ratio - | 1Y Target Price 1.06 |
Price to earnings Ratio - | 1Y Target Price 1.06 | ||
Volume (30-day avg) 1795044 | Beta 1.38 | 52 Weeks Range 0.24 - 5.83 | Updated Date 04/1/2025 |
52 Weeks Range 0.24 - 5.83 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.78 |
Earnings Date
Report Date 2025-03-07 | When - | Estimate -0.2233 | Actual -0.18 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -30.25% | Return on Equity (TTM) -77.48% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -46701266 | Price to Sales(TTM) - |
Enterprise Value -46701266 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.08 | Shares Outstanding 59215800 | Shares Floating 37016978 |
Shares Outstanding 59215800 | Shares Floating 37016978 | ||
Percent Insiders 0.33 | Percent Institutions 77.71 |
Analyst Ratings
Rating 4.62 | Target Price 7 | Buy 3 | Strong Buy 5 |
Buy 3 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Elevation Oncology Inc
Company Overview
History and Background
Elevation Oncology Inc. was founded in 2019 and focuses on developing targeted therapies for cancer patients with genomic alterations regardless of tumor type. The company has focused on identifying and developing targeted therapies for underserved cancer populations.
Core Business Areas
- Oncology Drug Development: Focuses on the research, development, and commercialization of targeted therapies for cancer patients with specific genomic alterations.
- Biomarker-Driven Therapies: Develops therapies that target specific biomarkers found in tumors, allowing for personalized treatment approaches.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
Leadership and Structure
Shawn M. Leland, PharmD, is the President and CEO. The company has a board of directors and a management team overseeing research, clinical development, and business operations.
Top Products and Market Share
Key Offerings
- EO-3021: EO-3021 (SyreniX) is a potential best-in-class antibody-drug conjugate (ADC) targeting Claudin 18.2. Currently in clinical trials. Competitors include Astellas (IMAB) with zolbetuximab. Market share is currently 0 due to being in clinical trials but with potential block buster numbers.
Market Dynamics
Industry Overview
The oncology market is characterized by intense competition, rapid innovation, and increasing demand for targeted therapies. The biomarker-driven approach is gaining traction as personalized medicine becomes more prevalent.
Positioning
Elevation Oncology is positioned as a targeted therapy company focused on genomic alterations regardless of tumor type, differentiating itself through precision medicine approaches.
Total Addressable Market (TAM)
The global oncology market is expected to reach hundreds of billions of dollars. Elevation Oncology is positioned to capture a share of this TAM by focusing on specific genomic alterations.
Upturn SWOT Analysis
Strengths
- Focus on biomarker-driven therapies
- Strong leadership team
- Potential for pipeline expansion
- Targeting underserved patient populations
Weaknesses
- Limited number of products in the market
- Reliance on clinical trial success
- High cash burn rate typical of biotech companies
- Limited brand recognition
Opportunities
- Partnerships and collaborations with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Regulatory approvals for key drug candidates
- Increasing adoption of personalized medicine
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- ASTL.SW
- MRTX
- ARRY
Competitive Landscape
Elevation Oncology competes with larger pharmaceutical companies and other biotech firms developing targeted therapies. It differentiates itself through its focus on genomic alterations regardless of tumor type.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily reflected in the advancement of its clinical pipeline.
Future Projections: Future growth is contingent on the successful completion of clinical trials and regulatory approvals for EO-3021 and other pipeline candidates. Analyst estimates vary widely.
Recent Initiatives: Focus on clinical trials for EO-3021. Strategic partnerships and collaborations to expand its pipeline and capabilities.
Summary
Elevation Oncology is a clinical-stage biotech company focused on developing targeted therapies for cancer. The company's success hinges on the clinical trial results for EO-3021. High risk investments exist and management will need to avoid pitfalls. The company will need to manage the inherent risks of biotech investments.
Similar Companies
- MRTX
- ARRY
- ZYME
Sources and Disclaimers
Data Sources:
- Elevation Oncology Inc. SEC filings
- Company press releases
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The biotech industry is inherently risky, and investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Elevation Oncology Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-06-25 | CEO, President & Director Mr. Joseph J. Ferra Jr. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 34 | Website https://elevationoncology.com |
Full time employees 34 | Website https://elevationoncology.com | ||
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. It's lead candidate is EO-3021, an antibody-drug conjugate (ADC) comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload that is in Phase 1 clinical trial as a monotherapy and in combinations with dostarlimab, a PD-1 inhibitor, and ramucirumab, a VEGFR2 inhibitor, in patients with advanced, unresectable, or metastatic gastric/gastroesophageal junction solid tumors. The company is also developing EO-1022, an ADC containing seribantumab, a fully human immunoglobulin G2 (IgG2) anti-HER3 mAb, and an MMAE payload, with glycan site-specific conjugation for the treatment of patients with HER3-expressing solid tumors, including breast cancer, non-small cell lung cancer, and other solid tumors. It has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021 for the treatment of cancer. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.